Bienvenue sur le forum !
Si vous souhaitez rejoindre la communauté, cliquez sur l'un de ces boutons !
>> Forum privé (partage d'analyses)
Catégories
- 1.2K Toutes les catégories
- 3 Autres classes d'actifs
- 4 Podcast
- 15 Débuter en Bourse
- 6 Club partage d'analyses
- 19 Portefeuilles
- 31 Medici
- 39 Finances personnelles
- 393 Discussion sur un titre
- 16 Livres
- 469 La Bourse en général
- 42 Fiscalité
- 59 L'économie en général
- 34 Pas de rapport avec la Bourse
- 60 Rencontre 5 à 7
- 21 Humour
- 49 Forum
Biosyent (rx-v)
Connectez-vous ou Inscrivez-vous pour commenter.
Réponses
http://watch.bnn.ca/#clip1071023 (entrevue de 8:15 avec Donville Kent Asset Management)
http://finance.yahoo.com/news/biosyent-pharma-signs-exclusive-licence-130000235.html
TORONTO, ONTARIO--(Marketwired - March 12, 2014) -BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Fiscal 2013 and Fourth Quarter (Q4 2013) financial results. Key highlights include:
Full year 2013 Sales of $7,799,426 increased by 55% versus 2012
Revenue has grown at a compound annual growth rate (CAGR) of 67% over the last three years
Full year 2013 Pharmaceutical Sales of $6,969,031 increased by 63% versus 2012
Seventeen consecutive quarters of continued pharmaceutical sales growth
2013 Net Income Before Tax of $2,452,840 increased year over year by 75%
2013 Tax Expense (net of deferred tax credit) was $524,812 versus ($142,195) in 2012
Net Income After Tax of $1,928,028 increased by 25% versus 2012
2013 Basic EPS of $0.14; Fully Diluted EPS of $0.13
Cash Generation in 2013 of $2,065,082 was 64% higher than 2012
The company ended 2013 with $4,405,910 in working capital of which cash was $4,381,137
The company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada
Selected as a TSX Venture 50 Top Performer for three consecutive years - 2012, 2013 and 2014
Named as one of Canada's fastest growing companies in the Profit 500 rankings for 2013
2 New Products submitted to Health Canada awaiting marketing approval
Pre-launch activity for a new Women's Health product - launch planned for second quarter of 2014
Pre-launch activity for a new Gastrointestinal Health product - launch planned for fourth quarter of 2014
Total sales for Q4 2013 of $2,142,835, were 61% higher compared to $1,327,953 in the corresponding prior year period. On a full year basis, sales in 2013 of $7,799,426 were 55% higher than the previous year sales $5,024,154.
Income Before Tax for Q4 2013 was $619,124, which was 71% higher than $361,237 in Q4 2012. Net Income Before Tax for full year 2013 was $2,452,840, an increase of 75% over the corresponding prior year period.
The Company recognized a deferred tax credit of $232,199 in the fourth quarter of 2012. The Company further recognized a deferred tax credit of $123,332 in the fourth quarter of 2013. These deferred tax credits pertain to the full year of 2012 and 2013. The increase of Net Income After Tax in the fourth quarter of 2013 is 59% over the fourth quarter of 2012 reckoned without these deferred tax credits.
The Company has provided for tax of $524,812 (net of deferred tax credit) in 2013 versus ($142,195) in 2012. Inspite of this difference in tax expense, Net Income After Tax increased by 25% from $1,541,317 in 2012 to $1,928,028 in 2013.
Working capital, which is the difference between current assets and current liabilities, increased by 76% from $2,509,278 as at December 31, 2012 to $4,405,910 as at December 31, 2013. Total Cash included in working capital on December 31, 2013 was $4,381,137. Total Shareholder's Equity increased by 71% from $2,839,409 at December 31, 2012 to $4,854,630 at December 31, 2013. This is mainly due to an increase in retained earnings in 2013.
On October 1, 2013 the Company signed an exclusive Canadian Licence and Distribution Agreement with a new European Partner for a Women's Health product that has prior approval from Health Canada. The Company plans to launch the product in the second quarter of 2014.
Subsequent to year-end, BioSyent in-licensed a new Gastrointestinal Health product from an existing European partner. This product is approved by Health Canada and is being prepared for launch in Q4 2014.
The Company's Consolidated Financial Statements and Management's Discussion & Analysis will be posted on www.sedar.com on March 12, 2013.
http://www.biosyent.com/q4/#.UyBegZK9KK1
C'est évident que Biosyent fera pas 0.13$ bpa en 2014.
On devrait toucher le 0.20$ bpa en 2014. Si on soustrait le Cash/ action et anticipe un 0.20$ bpa le Ratio tombe à C/B 22 .
C'est pas donné mais le prix a payer si on veut un titre qui risque de croitre au dessus de 30% le plus longtemps possible espérons.
Dans la présentation suivante au LD micro:
http://wsw.com/webcast/ldmicro5/bioyf/
à la diapo 6, la compagnie a assez de pipeline visibility pour émettre un forward looking statement qui dit qu'elle s'attend à un CAGR de 30% minimum entre 2013 et 2018. Le PEG est donc proche de 1 sur cette base. Le titre est un hold selon moi... Avec l'embauche des nouveaux pharma reps je pense que nous verrons une baisse de la marge de profit les 2 prochains trimestres, en raison des up-front costs pour le launch du produit au Q2 et un autre au Q4. Je pense que 2015 sera une bonne année au niveau croissance des ventes. Si vous parlez au CEO il vous dira de modéliser un EBITDA margin de 25%, il vous dira que le 30%-35% actuel n'est pas soutenable à LT. Ceci dit, il a tendance à surprendre vers le haut.
Product Pipeline
InAugust 2012 BioSyent Pharma Inc. signed an exclusive Licensing and Distribution
Agreement with a European partner for two new products that will be marketed to
Hospitals. These two urgent care drugs are supplied in a patented delivery
system that offers technical advantages over existing alternatives and will be
used in hospitals and acute care settings. The two new products were filed with
Health Canada in Q2 2013. The Company will launch these products upon receiving
approval. These products will provide hospitals, clinics, and healthcare
professionals with improved patient safety as well as operational efficiencies
and will complement BioSyents Hospital Division business.
There are several additional products under development by our European partner and we
look forward to exploring additional product candidates utilizing the same
patented technology. Due diligence on the third product using this technology
has commenced. The Company is also in discussion with several other potential
partners for other new product opportunities.
New
Capabilities and Awards
The Company continues to invest behind its sales and marketing efforts in its
pharmaceutical business and consequently has experienced continued growth in the
pharmaceutical segment of the business which grew 63% in 2013 over the previous
year 2012.
TheCompany is investigating out-licencing opportunities for the sale and
distribution of FeraMAX® 150 and FeraMAX® Powder brands in international markets
and has appointed a Sales Manager to accelerate exports of the FeraMAX®
brand.
Is BioSyent The Next Paladin Labs ?
http://www.cantechletter.com/2014/03/biosyent-next-paladin-labs/
Le prix de l'action de Biosyent s'est envolé quand Palladin a été acheté. Je pense que le marché considère déjà ce fait et que le prix de l'action reflète cette posibilité.
Snowball, tu es très actif ici et sur corner en ce qui concerne Biosyent. Quel pourcentage de portefeuille as-tu dans RX?
Very, very good management team. Some really good products. Has a lot of
cash. Very high ROE. He owns it, but doesn’t have a massive position in
it because it is quite a small company. A good, long-term growth story.
Symptomatic of the issues of a lot of the great growth companies, i.e.,
they were trading in the single digit PE ratios but are now trading in
the high teens or mid-20s. Not cheap, but a great one.